3.3
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Certain large, lipid-insoluble drug molecules that resemble amino acids, peptides, or glucose, require specialized carrier proteins to facilitate thei…
Large lipid-insoluble drug molecules resembling amino acids, peptides, or glucose require special carrier proteins for diffusion across the cell membrane.
The transport can occur without an energy input—known as facilitated diffusion or at the expense of energy—termed active transport.
Facilitated diffusion is a passive process involving SLC transporters that bind to the drug, undergo conformational changes, and release the drug on the other side.
In active transport, the drug moves against its concentration gradient. It can be further categorized based on the driving force.
In primary active transport, ABC transporters use energy from ATP hydrolysis to mediate the unidirectional efflux of the drugs.
In secondary active transport, SLC transporters move drugs against their concentration gradient. This is driven by the electrochemical potential resulting from the movement of another solute along its gradient.
Symport is when the two move in the same direction; antiport is when they move in opposite directions.
View the full transcript and gain access to JoVE Core videos
Q1: Why do large lipid-insoluble drug molecules need carrier proteins to cross cell membranes?
Large lipid-insoluble drugs resembling amino acids, peptides, or glucose cannot dissolve in the lipid bilayer and pass through directly. Specialized carrier proteins bind these molecules and facilitate their transport across the membrane through either facilitated diffusion or active transport, enabling absorption despite their chemical properties.
Q2: What is the difference between facilitated diffusion and active transport for drug absorption?
Facilitated diffusion is a passive process using SLC transporters that move drugs down their concentration gradient without energy input. Active transport moves drugs against their concentration gradient and requires energy from ATP hydrolysis or electrochemical gradients, enabling absorption of drugs that would otherwise accumulate outside cells.
Q3: How do SLC transporters facilitate drug movement across cell membranes?
SLC transporters bind to drug molecules, undergo conformational changes, and release the drug on the opposite side of the membrane. This process can occur passively through facilitated diffusion or actively through secondary active transport, where the electrochemical gradient of another solute drives drug movement.
Q4: What is primary active transport and how do ABC transporters mediate drug efflux?
Primary active transport uses ABC transporters that directly hydrolyze ATP to generate energy for unidirectional drug efflux across the cell membrane. This energy-dependent mechanism actively pumps drugs out of cells against their concentration gradient, independent of other solute movements and transporter conformational changes.
Q5: How does secondary active transport move drugs against their concentration gradient?
Secondary active transport uses SLC transporters powered by the electrochemical potential created when another solute moves along its gradient. The drug couples to this solute movement, allowing uphill transport without direct ATP hydrolysis, occurring as either symport or antiport depending on directional coupling.
Q6: What is the difference between symport and antiport in secondary active transport?
Symport moves the drug and coupled solute in the same direction across the membrane, while antiport moves them in opposite directions. Both mechanisms harness electrochemical gradients to transport drugs against concentration gradients through SLC transporters without requiring direct ATP hydrolysis.
Q7: How do carrier-mediated transport mechanisms affect drug bioavailability?
Carrier-mediated transport determines whether lipid-insoluble drugs can be absorbed across cell membranes and enter systemic circulation. The efficiency of facilitated diffusion and active transport directly influences drug absorption rates and systemic availability, making transporter expression and function critical determinants of overall drug bioavailability.